title: Effect of temozolomide in patients with metastatic bronchial carcinoids.
abstract: BACKGROUND
  Metastatic bronchial carcinoids are rare neoplasms, where efforts of medical treatment so far have been disappointing. A previous study from our center indicated that temozolomide might be of value.
  
  
  METHODS
  All patients with progressive metastatic bronchial carcinoid treated with temozolomide as monotherapy at our center between 2004 and 2010 (n = 31) were included in this retrospective study. 14 tumors were classified as typical and 15 as atypical carcinoids, whereas 2 tumors could not be classified. Temozolomide was given on 5 consecutive days every 4 weeks. Toxicity was evaluable in 28 of 31 patients, and 22 patients were evaluable by RECIST 1.1.
  
  
  RESULTS
  There were no complete responses. A partial response was seen in 3 patients (14%), stable disease in 11 (52%) and progressive disease in 7 patients (33%). Median progression-free survival was 5.3 months and median overall survival was 23.2 months from the start of temozolomide. Toxicities grade 3-4 were noted in 4 patients, thrombocytopenia (n = 3) and leukopenia (n = 1).
  
  
  CONCLUSIONS
  Temozolomide as monotherapy shows activity in metastatic bronchial carcinoids. Regimens combining temozolomide with other agents (e.g. capecitabine and/or bevacizumab, everolimus, radiolabeled somatostatin analogues) should be further studied in these patients.
authors: Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
authors: Joakim
authors: J
authors: Crona
authors: Irina
authors: I
authors: Fanola
authors: Daniel P
authors: DP
authors: Lindholm
authors: Pantelis
authors: P
authors: Antonodimitrakis
authors: Kjell
authors: K
authors: Öberg
authors: Barbro
authors: B
authors: Eriksson
authors: Dan
authors: D
authors: Granberg
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology* / Q000627:therapeutic use; D001984:Bronchial Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002276:Carcinoid Tumor / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D015331:Cohort Studies; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012189:Retrospective Studies; D000077204:Temozolomide; D055815:Young Adult
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide